Tearing down the walls: FDA approves next generation sequencing (NGS) assays for actionable cancer genomic aberrations
暂无分享,去创建一个
Laura Conti | Gennaro Ciliberto | G. Ciliberto | E. Pescarmona | A. Martayan | A. Fabi | S. Buglioni | L. Conti | P. Giacomini | M. Allegretti | Edoardo Pescarmona | Patrizio Giacomini | Simonetta Buglioni | Alessandra Fabi | Matteo Allegretti | Aline Martayan | Laura Conti
[1] P. Froguel,et al. Contribution of type 2 diabetes associated loci in the Arabic population from Tunisia: a case-control study , 2009, BMC Medical Genetics.
[2] Linghua Wang,et al. From human genome to cancer genome: The first decade , 2013, Genome research.
[3] Donavan T. Cheng,et al. Precision medicine at Memorial Sloan Kettering Cancer Center: clinical next-generation sequencing enabling next-generation targeted therapy trials. , 2015, Drug discovery today.
[4] Donavan T. Cheng,et al. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology. , 2015, The Journal of molecular diagnostics : JMD.
[5] Alan Ashworth,et al. BRCAness revisited , 2016, Nature Reviews Cancer.
[6] B. Taylor,et al. Implementing Genome-Driven Oncology , 2017, Cell.
[7] Ahmet Zehir,et al. Comprehensive detection of germline variants by MSK-IMPACT, a clinical diagnostic platform for solid tumor molecular oncology and concurrent cancer predisposition testing , 2017, BMC Medical Genomics.